

## **InNexus' CEO to Present at the 6th Annual BioPartnering North America Conference**

***February 3-5, 2008, in Vancouver, BC Canada***

### **Jeff Morhet to Discuss Company Highlights and Recent Developments**

BRITISH COLUMBIA, Canada – January 30, 2008 - InNexus Biotechnology Inc.'s (OTCBB:IXSBF; TSX VENTURE: IXS; <http://www.ixsbio.com>) Chairman and Chief Executive Officer, Jeff Morhet, will give an Open House Podium Presentation at the 6th Annual BioPartnering North America Conference. The presentation will be held on Tuesday, February 5, 2008 at 10:45 AM PST, in the Thompson Room at the Westin Bayshore Resort & Mariana, Vancouver, BC Canada. Mr. Morhet will provide a brief overview of the company, its Dynamic Cross Linking technology (DXL™), alliances and an update on research progress and clinical developments.

### **About BioPartnering North America**

BioPartnering North America (BPN) is North America's most innovative partnering conference for the life sciences, offering seventy-eight company presentations, partnering software, interactive sessions and workshops, and the best networking opportunities with business development executives in the life sciences.

Co-hosted by LifeSciences British Columbia, BIOTECCanada, and BioAlberta, BPN annually attracts senior business development executives from around the globe. BPN offers a targeted approach to the best lifescience partnering opportunities.

### **About InNexus**

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel, and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit [www.ixsbio.com](http://www.ixsbio.com).

### **Forward-Looking Statements**

This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation,

statements regarding future drug development activities or anticipated products, anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

**Contact:**

InNexus Biotechnology Inc.  
Wade Brooksby, Chief Financial Officer  
480-862-7500